<?xml version="1.0" encoding="UTF-8"?>
<EmailTemplate xmlns="http://soap.sforce.com/2006/04/metadata">
    <available>true</available>
    <description>New design applied</description>
    <encodingKey>ISO-8859-1</encodingKey>
    <name>bcc_Guardant360_CRC_Patient</name>
    <style>none</style>
    <subject>{!Guardant_360_Sample__c.Name} report delivered to {!Contact.Name}</subject>
    <textOnly>Salesforce link for GH use: {!Guardant_360_Sample__c.Name}

Copy of the email sent to {!Contact.Full_Name__c} shown below:

*****

Dear Dr. {!Contact.Full_Name__c},

Thank you for choosing Guardant360, the gold standard in comprehensive liquid biopsy. Guardant360 covers all guideline-recommended somatic markers in solid tumors. The patient sample you submitted on {!Guardant_360_Sample__c.Date_Received__c} has been processed and is ready for your review.

VIEW YOUR REPORT at https://portal.guardanthealth.com/r/{!Guardant_360_Sample__c.Name}

In &gt;20,000 clinical samples across multiple tumor types, Guardant360 has detected alterations associated with response to:

– FDA-approved, on-label therapies in 14-18% of samples
– FDA-approved, on- or off-label therapies in 46-51% of samples
– Any therapy, including those in clinical trials, in most samples

Guardant360 is a 73-gene assay that tests for all guideline-recommended somatic genomic alterations for solid tumors, including these key alterations:

EGFR
Exon 19 deletion, L858R, G719, L861 and T790M point mutations, and all other sensitizing and resistance mutations

BRAF
V600E/K alterations and other sensitizing mutations

KRAS &amp; NRAS
G12, G13 (exon 2), A59, Q61 (exon 3), K117, A146 (exon 4) and other RAS resistance mutations

ERBB2 (HER2)
Amplifications and other sensitizing and resistance mutations and insertions- deletions (indels)

ALK
EML4-ALK and other fusions and resistance mutations

MET
Amplifications, exon 14 skipping mutations, sensitizing and resistance mutations

RET
Fusions and resistance mutations

ROS1
Fusions and resistance mutations

KIT
Sensitizing mutations and resistance mutations, indels and amplifications

PDGFRA
Sensitizing mutations and resistance mutations, indels and amplifications

Schedule a consultation

I am a genomics specialist and certified genetic counselor. After reviewing this report, please feel free to reply to this email or call 1.855.698.8887 to schedule a consultation with me.

Sincerely,
Christine Lee, M.S., C.G.C
Genomic Specialist, Medical Affairs
Guardant Health, Inc.
Ph: 855-698-8887
Fax: 888-974-4258
medicalaffairs@guardanthealth.com

CLIA Certified # 05D2070300 | CAP Accredited # 8765297

To change your notification preferences, please login to your portal account at https://portal.guardanthealth.com.

This message is intended solely for the designated recipient(s). It may contain confidential or proprietary information and may be subject to attorney-client privilege or other confidentiality protections. If you are not a designated recipient you may not review, copy or distribute this message. If you receive this in error, please notify the sender by reply e-mail and delete this message. Thank you.

TST-GDL-009 V1</textOnly>
    <type>custom</type>
    <uiType>Aloha</uiType>
</EmailTemplate>
